NMN intervention-associated changes will be evaluated across predefined domains:
- Clinical examination parameters, such as:
- Bone mineral density (g/cm²)
- Pulmonary function, including FEV1 (L), FVC (L), and FEV1/FVC (%) Each parameter will be analyzed individually.
- Functional performance measures, such as:
- Grip strength (kg)
- Purdue Pegboard Test completion time (s) Improvement is defined as an increase in grip strength and a decrease in completion time.
- Inflammatory and clinical biomarkers, such as:
Circulating inflammatory markers (e.g., IL-6 [pg/mL], CRP [mg/L]) Improvement is defined as a reduction in these markers.
- Multi-omics-derived aging biomarkers, such as:
Gene expression, proteomic, and metabolomic profiles related to metabolism, immunity, and aging. These measures will be summarized using:
Predefined composite aging scoresm, biological ages, or principal component-based or pathway-level summaries, depending on the analysis framework.